Lucid Diagnostics Stock Alpha and Beta Analysis
| LUCD Stock | USD 0.77 0.02 2.37% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lucid Diagnostics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lucid Diagnostics over a specified time horizon. Remember, high Lucid Diagnostics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lucid Diagnostics' market risk premium analysis include:
Beta 0.31 | Alpha (0.09) | Risk 3.05 | Sharpe Ratio (0.04) | Expected Return (0.12) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Lucid |
Lucid Diagnostics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lucid Diagnostics market risk premium is the additional return an investor will receive from holding Lucid Diagnostics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lucid Diagnostics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lucid Diagnostics' performance over market.| α | -0.09 | β | 0.31 |
Lucid Diagnostics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lucid Diagnostics' Buy-and-hold return. Our buy-and-hold chart shows how Lucid Diagnostics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Lucid Diagnostics Market Price Analysis
Market price analysis indicators help investors to evaluate how Lucid Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lucid Diagnostics shares will generate the highest return on investment. By understating and applying Lucid Diagnostics stock market price indicators, traders can identify Lucid Diagnostics position entry and exit signals to maximize returns.
Lucid Diagnostics Return and Market Media
The median price of Lucid Diagnostics for the period between Tue, Sep 17, 2024 and Mon, Dec 16, 2024 is 0.85 with a coefficient of variation of 10.09. The daily time series for the period is distributed with a sample standard deviation of 0.09, arithmetic mean of 0.88, and mean deviation of 0.08. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Lucid Diagnostics Holds Inaugural CheckYourFoodTube Precancer Testing Event for Former NFL Players | 10/01/2024 |
2 | CVRx Reports Q3 Loss, Tops Revenue Estimates | 10/29/2024 |
3 | Lucid Diagnostics ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publicatio... | 11/07/2024 |
4 | Neuronetics Reports Q3 Loss, Lags Revenue Estimates | 11/12/2024 |
5 | Needham maintains Buy rating on Lucid Diagnostics shares | 11/13/2024 |
6 | Lucid Diagnostics Earns Buy Rating from Canaccord Genuity Group | 11/14/2024 |
7 | Lucid Diagnostics Inc. announced that it expects to receive 21.75 million in funding - Marketscreener.com | 11/19/2024 |
8 | Lucid Diagnostics Strategic Financial Maneuvering and Agreements - Nasdaq | 11/29/2024 |
9 | Tesla To 370 Here Are 10 Top Analyst Forecasts For Monday | 12/09/2024 |
10 | Disposition of tradable shares by Sokolov Jacque J of Lucid Diagnostics subject to Rule 16b-3 | 12/10/2024 |
About Lucid Diagnostics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lucid or other stocks. Alpha measures the amount that position in Lucid Diagnostics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.39 | 3.42 | 5.22 | 5.48 | Days Of Inventory On Hand | 307.6 | 11.21 | 16.97 | 16.12 |
Lucid Diagnostics Upcoming Company Events
As portrayed in its financial statements, the presentation of Lucid Diagnostics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lucid Diagnostics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lucid Diagnostics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lucid Diagnostics. Please utilize our Beneish M Score to check the likelihood of Lucid Diagnostics' management manipulating its earnings.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Lucid Diagnostics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Lucid Diagnostics Backtesting, Lucid Diagnostics Valuation, Lucid Diagnostics Correlation, Lucid Diagnostics Hype Analysis, Lucid Diagnostics Volatility, Lucid Diagnostics History and analyze Lucid Diagnostics Performance. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Lucid Diagnostics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.